Tscan Therapeutics, Inc. (tcrx): Q1 2026 Results with Improved Net Loss

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering t

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026.

TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks

TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The company reported revenue of $1.0 million versus $2.2 million in the prior-year quarter, reflecting lower research activity tied to its collaboration with Amgen. Research and development expenses totaled $21.9 million compared to $29.8 million a year earlier, while general and administrative expenses were $8.2 million versus $8.6 million, driven mainly by reduced professional costs and timing of spending.

The corporation’s net loss improved to $28.7 million from $34.1 million, supported by $0.5 million in net interest income compared with $2.1 million previously. Cash and cash equivalents stood at $128.1 million as of March 31, 2026, excluding $5.0 million restricted cash, with a runway expected into the second half of 2027. The update also outlined pipeline progress across heme malignancies, solid tumors, and autoimmune programs, including upcoming clinical milestones and preclinical developments.

Leave a Reply

Your email address will not be published. Required fields are marked *